A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : PPK / population pharmacokinetic

[Related PubMed/MEDLINE]
Total Number of Papers: 171
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   PPK  (>> Co-occurring Abbreviation)
Long Form:   population pharmacokinetic
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 An Improved LC-MS/MS Method for Determination of Docetaxel and Its Application to Population Pharmacokinetic Study in Chinese Cancer Patients. IS
2020 Factors contributing to the systemic clearance of infliximab with long-term administration in Japanese patients with Crohn's disease: Analysis using population pharmacokinetics
. ATI, CD, CL, IFX
2020 Model extrapolation to a real-world dataset: evaluation of tacrolimus population pharmacokinetics and drug interaction in pediatric liver transplantation patients. ---
2020 Population pharmacokinetic analysis of intravenous busulfan: GSTA1 genotype is not a predictive factor of initial dose in Chinese adult patients undergoing hematopoietic stem cell transplantation. CL, HSCT, PK
2020 Population Pharmacokinetic Analysis of Isoniazid among Pulmonary Tuberculosis Patients from China. NAT2, PK, TB
2020 Population Pharmacokinetic Analysis of Tiropramide in Healthy Korean Subjects. PK
2020 Population Pharmacokinetic Model to Assess the Impact of Disease State on Thalidomide Pharmacokinetics. HIV, MM, V/F
2020 Population pharmacokinetic study of tacrolimus in pediatric patients with primary nephrotic syndrome: A comparison of linear and nonlinear Michaelis-Menten pharmacokinetic model. MM, NONMEM, PNS, TAC
2020 Population pharmacokinetics and dosing regimen optimization of tacrolimus in Chinese pediatric hematopoietic stem cell transplantation patients. HSCT, NONMEM
10  2020 Population pharmacokinetics and initial dosing regimen optimization of cyclosporin in pediatric hemophagocytic lymphohistiocytosis patients. HLH
11  2020 Population pharmacokinetics of high-dose methotrexate in Chinese pediatric patients with medulloblastoma. CL, CrCl, DEX, FOCE, HD-MTX, MTX, WT
12  2020 Population Pharmacokinetics of Ipilimumab in Combination With Nivolumab in Patients With Advanced Solid Tumors. CL
13  2020 Population pharmacokinetics of vancomycin in Chinese patients with augmented renal clearance. ARC, NONMEM
14  2020 UFLC-MS/MS Determination and Population Pharmacokinetic Study of Tanshinol, Ginsenoside Rb1 and Rg1 in Rat Plasma After Oral Administration of Compound Danshen Dripping Pills. CDDP, CMM, GRb1, GRg1, TSL
15  2019 A population pharmacokinetic model of vancomycin for dose individualization based on serum cystatin C as a marker of renal function. GFR, PTA
16  2019 Cyclosporin population pharmacokinetics in pediatric refractory nephrotic syndrome based on real-world studies: Effects of body weight and spirolactone administration. PRNS, V/F, WT
17  2019 Evaluation of Concentration Errors and Inappropriate Dose Tailoring of Tacrolimus Caused by Sampling-time Deviations in Pediatric Patients with Primary Nephrotic Syndrome. CE, DST, PNS, RCE, TDM
18  2019 Glomerular Filtration Rate Is a Major Predictor of Clearance of Oxcarbazepine Active Metabolite in Adult Chinese Epileptic Patients: A Population Pharmacokinetic Analysis. BW, CL, MHD, OXC
19  2019 Impact of Donor and Recipient CYP3A5*3 Genotype on Tacrolimus Population Pharmacokinetics in Chinese Adult Liver Transplant Recipients. TAC
20  2019 Model-Based Population Pharmacokinetic Analysis of Nivolumab in Chinese Patients With Previously Treated Advanced Solid Tumors, Including Non-Small Cell Lung Cancer. NPC, NSCLC, PK
21  2019 No Dose Adjustment for Isavuconazole Based on Age or Sex. AUC, CI, PK
22  2019 Population Pharmacokinetic Analysis of Phenytoin After Intravenous Administration of Fosphenytoin in Adult and Elderly Epileptic Patients. CL
23  2019 Population pharmacokinetic and pharmacogenetics of imatinib in Chinese patients with chronic myeloid leukemia. ---
24  2019 Population Pharmacokinetic Modeling of VL-2397, a Novel Systemic Antifungal Agent: Analysis of a Single- and Multiple-Ascending-Dose Study in Healthy Subjects. ---
25  2019 Population Pharmacokinetics and Bayesian Estimation of Mycophenolic Acid Exposure in Chinese Renal Allograft Recipients After Administration of EC-MPS. EC-MPS, MPA
26  2019 Population pharmacokinetics and dosage optimization of tacrolimus in pediatric patients with nephrotic syndrome
. NONMEM, V/F
27  2019 Population pharmacokinetics and dose simulation of oxcarbazepine in Chinese paediatric patients with epilepsy. GOF, MHD, NPDE, OXC, pcVPC, WT
28  2019 Population pharmacokinetics and dosing regimen optimisation of lopinavir in Chinese adults infected with HIV. HIV, LPV, PI, RSE, V/F
29  2019 Population pharmacokinetics of oxcarbazepine active metabolite in Chinese paediatric epilepsy patients and its application in individualised dosage regimens. BW, MHD, OXC, PK
30  2019 Population pharmacokinetics of sirolimus in pediatric patients with kaposiform hemangioendothelioma: A retrospective study. PKHE, V/F
31  2019 Population pharmacokinetics of tacrolimus in pediatric patients with systemic-onset juvenile idiopathic arthritis: Initial dosage recommendations. SoJIA
32  2019 Population pharmacokinetics of tacrolimus in pediatric refractory nephrotic syndrome and a summary of other pediatric disease models. EXP, PRNS, TAC, TDM, V/F
33  2019 Prediction of lefamulin epithelial lining fluid penetration after intravenous and oral administration using Phase 1 data and population pharmacokinetics methods. ELF, PK
34  2019 Sorafenib Population Pharmacokinetics and Skin Toxicities in Children and Adolescents with Refractory/Relapsed Leukemia or Solid Tumor Malignancies. HFSR
35  2019 Steady-state population pharmacokinetics of terizidone and its metabolite cycloserine in patients with drug-resistant tuberculosis. DR-TB
36  2019 The Evolution of Population Pharmacokinetic Model of Oral Phenytoin for Early Seizure Prophylaxis Post-Craniotomy. NONMEM, NPDEs
37  2019 Updated Population Pharmacokinetic Model of Cabozantinib Integrating Various Cancer Types Including Hepatocellular Carcinoma. PK
38  2019 Vancomycin pharmacokinetic model development in patients on intermittent online hemodiafiltration. Eec, fr, HD, HDF, MDAPE, MDPE
39  2019 Wuzhi capsule and haemoglobin influence tacrolimus elimination in paediatric kidney transplantation patients in a population pharmacokinetics analysis: A retrospective study. NONMEM
40  2019 [The Current State and Future Prospects of Population Pharmacokinetic Research in Post-marketing Clinical Studies in Japan]. IF, PI
41  2018 A Population Pharmacokinetic-Pharmacogenetic Model of Lamotrigine in Chinese Children With Epilepsy. LTG
42  2018 A population pharmacokinetic/toxicity model for the reduction of platelets during a 48-h continuous intravenous infusion of the histone deacetylase inhibitor belinostat. HDI, PD
43  2018 An LC-MS/MS Method for Absolute Quantification of Nivolumab in Human Plasma: Application to Clinical Therapeutic Drug Monitoring. PD-1
44  2018 Pharmacokinetics and Pharmacodynamic Target Attainment of Benzylpenicillin in an Adult Severely Ill Sub-Saharan African Patient Population. CrCl, MIC
45  2018 Population Pharmacokinetic Analysis of Asunaprevir in Subjects with Hepatitis C Virus Infection. AST, ASV, AUC, CYP3A4, HCV
46  2018 Population pharmacokinetic modeling of flurbiprofen, the active metabolite of flurbiprofen axetil, in Chinese patients with postoperative pain. ---
47  2018 Population pharmacokinetics (PPK) of anamorelin (ANAM), an oral selective ghrelin receptor agonist. ANAM
48  2018 Population Pharmacokinetics and Dosing Optimization of Azithromycin in Children with Community-Acquired Pneumonia. CAP
49  2018 Population pharmacokinetics of 25-hydroxy vitamin D in children with asthma
. DD, HPA, NONMEM
50  2018 Population Pharmacokinetics of Apixaban in Subjects With Nonvalvular Atrial Fibrillation. NVAF, P-gp
51  2018 Population pharmacokinetics of lamotrigine co-administered with valproic acid in Chinese epileptic children using nonlinear mixed effects modeling. LTG, NONMEM, VPA
52  2018 Population pharmacokinetics of tacrolimus in children with nephrotic syndrome. NS, TAC
53  2018 Population pharmacokinetics of tacrolimus in paediatric systemic lupus erythematosus based on real-world study. NONMEM, pSLE, V/F, VPC
54  2018 Population pharmacokinetics of theophylline in adult Chinese patients with asthma and chronic obstructive pulmonary disease. FFM
55  2018 Population pharmacokinetics of valproic acid in epileptic children: Effects of clinical and genetic factors. GOF, NONMEM, NPDE, PK, VPA, VPC
56  2018 Vancomycin therapeutic drug monitoring and population pharmacokinetic models in special patient subpopulations. TDM
57  2017 A population pharmacokinetic model for individualised dosage regimens of vancomycin in Chinese neonates and young infants. PK
58  2017 Experience and pharmacokinetics of Levetiracetam in Korean neonates with neonatal seizures. LEV
59  2017 Further Evaluation of Covariate Analysis using Empirical Bayes Estimates in Population Pharmacokinetics: the Perception of Shrinkage and Likelihood Ratio Test. EBEs, LRT
60  2017 Impact of CYP2C19 Genotype and Liver Function on Voriconazole Pharmacokinetics in Renal Transplant Recipients. AST, CL, IFI, RTRs, VRC
61  2017 Mizoribine therapy combined with steroids and mizoribine blood concentration monitoring for idiopathic membranous nephropathy with steroid-resistant nephrotic syndrome. CR, IMN, MZR, PSL, SRNS
62  2017 Population Pharmacokinetic Analysis of Daclatasvir in Subjects with Chronic Hepatitis C Virus Infection. AUCss, HCV, RSE
63  2017 Population Pharmacokinetic and Exposure-Response Analysis of Weekly Teriparatide in Osteoporosis Patients. AUC, BMD
64  2017 Population pharmacokinetic models of lamotrigine in different age groups of Chinese children with epilepsy. 0.463VPA, CL, LTG, MAE, MPE, NONMEM, RMSE, Vd
65  2017 Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in Chinese liver transplant patients. AUC, CLCR, POD, TAC, TDM
66  2017 Population pharmacokinetics of cyclosporine A in Japanese renal transplant patients: comprehensive analysis in a single center. BSA, CyA, PK
67  2017 Population Pharmacokinetics of Eplerenone in Japanese Patients With Chronic Heart Failure. CHF, CLCR, PK
68  2017 Population pharmacokinetics of ospemifene and safety evaluation of pharmacokinetic alterations caused by intrinsic and extrinsic factors
. ---
69  2017 Population pharmacokinetics of pomalidomide in patients with relapsed or refractory multiple myeloma with various degrees of impaired renal function. RRMM
70  2017 Population Pharmacokinetics of Topiramate in Japanese Pediatric and Adult Patients With Epilepsy Using Routinely Monitored Data. ---
71  2017 The true distribution volume and bioavailability of mizoribine in children with chronic kidney disease. MZR, PSPKD, Vd
72  2017 Utilization of population pharmacokinetics in drug development and provision of the results to healthcare professionals
. PD, US
73  2017 [Population pharmacokinetics of vancomycin from severe in patients with lower respiratory tract infection]. CL, NONMEM, RICU
74  2016 An integrative population pharmacokinetics approach to the characterization of the effect of hepatic impairment on clobazam pharmacokinetics. LGS, N-CLB
75  2016 Drug-metabolism mechanism: Knowledge-based population pharmacokinetic approach for characterizing clobazam drug-drug interactions. AEDs, DDIs, LGS, N-CLB, PK
76  2016 Duration of Systemic Inflammatory Response Syndrome Influences Serum Vancomycin Concentration in Patients With Sepsis. CrCl, SIRS, VCM
77  2016 Improvement of Predictivity of Teicoplanin Serum Trough Concentrations at Steady State Calculated by Vancomycin Pharmacokinetic Parameter. CL, TEIC, VCM
78  2016 Influences of CYP2D6*10 polymorphisms on the pharmacokinetics of iloperidone and its metabolites in Chinese patients with schizophrenia: a population pharmacokinetic analysis. ---
79  2016 Isavuconazole Population Pharmacokinetic Analysis Using Nonparametric Estimation in Patients with Invasive Fungal Disease (Results from the VITAL Study). AUC, BMI, CL, eGFR, IA, IFD, PK
80  2016 Model-based approaches for ivabradine development in paediatric population, part I: study preparation assessment. PBPK, PK
81  2016 Model-based meta-analysis for development of a population-pharmacokinetic (PPK) model for Vitamin D3 and its 25OHD3 metabolite using both individual and arm-level data. ---
82  2016 Montelukast in the treatment of perennial allergic rhinitis in paediatric Japanese patients; an open-label clinical trial. AE, CT, OG, PAR
83  2016 Optimal dosing regimen of biapenem in Chinese patients with lower respiratory tract infections based on population pharmacokinetic/pharmacodynamic modelling and Monte Carlo simulation. CLCR, LRTIs, PK/PD, PTA
84  2016 Population pharmacokinetic modeling and noncompartmental analysis demonstrated bioequivalence between metformin component of metformin/vildagliptin fixed-dose combination products and metformin immediate-release tablet sourced from various countries. FDC, IR
85  2016 Population pharmacokinetic modeling and simulation of huperzine A in elderly Chinese subjects. AD
86  2016 Population pharmacokinetic modeling of oxcarbazepine active metabolite in Chinese patients with epilepsy. AST, BUN, etaV, Hgb, MHD
87  2016 Population Pharmacokinetics Analysis To Inform Efavirenz Dosing Recommendations in Pediatric HIV Patients Aged 3 Months to 3 Years. CL, EFV, Vc, Vp
88  2016 Population Pharmacokinetics and Dosing Regimen Optimization of Meropenem in Cerebrospinal Fluid and Plasma in Patients with Meningitis after Neurosurgery. CSF, PTA
89  2016 Population Pharmacokinetics and Pharmacodynamics of Piperacillin/Tazobactam in Patients with Nosocomial Infections. CL, CLCR, HPLC, PIP, PTA, TAZ
90  2016 Population Pharmacokinetics of Isavuconazole from Phase 1 and Phase 3 (SECURE) Trials in Adults and Target Attainment in Patients with Invasive Infections Due to Aspergillus and Other Filamentous Fungi. AUC, AUC0-24, PD, PTA
91  2016 Population Pharmacokinetics of Phenytoin Based on NONMEM in Patients with Intracranial Tumor During the First Week of Post-Craniotomy. NONMEM
92  2016 Population pharmacokinetics of vancomycin in adult Chinese patients with post-craniotomy meningitis and its application in individualised dosage regimens. PCM, VCM
93  2016 Study design and implementation for population pharmacokinetics of Chinese medicine: An expert consensus. CM
94  2016 Using Population Pharmacokinetic and Pharmacodynamic Analyses of Entecavir in Pediatric Subjects to Simplify Dosing Recommendations. CHB, E max, HBV, PPD
95  2016 [A study of population pharmacokinetics of linezolid in Chinese]. ---
96  2015 Development of a population PK model of tacrolimus for adaptive dosage control in stable kidney transplant patients. AUC, PK
97  2015 Limited sampling strategies for therapeutic drug monitoring of amikacin and kanamycin in patients with multidrug-resistant tuberculosis. IQR, MDR-TB
98  2015 Population pharmacokinetics and pharmacodynamics of busulfan with GSTA1 polymorphisms in patients undergoing allogeneic hematopoietic stem cell transplantation. AUCs
99  2015 Population pharmacokinetics of 25-hydroxyvitamin D in healthy young adults. CL, DD, MOF, NONMEM, PHO
100  2015 Population pharmacokinetics of high-dose methotrexate after intravenous administration in Chinese osteosarcoma patients from a single institution. HD-MTX, NONMEM, PK